EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

WuXi PharmaTech (Cayman Stock Hits New 52-Week Low (WX)

By TheStreet Wire 12/12/11 - 10:21 AM EST

Find out if (WX) is in Cramer's Portfolio.

NEW YORK (TheStreet) -- WuXi PharmaTech (Cayman (NYSE:WX) hit a new 52-week low Monday as it is currently trading at $10.84, below its previous 52-week low of $10.95 with 11,161 shares traded as of 9:56 a.m. ET. Average volume has been 277,600 shares over the past 30 days.

WuXi PharmaTech (Cayman has a market cap of $830 million and is part of the health care sector and drugs industry. Shares are down 31.2% year to date as of the close of trading on Friday.

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company primarily in the People's Republic of China and the United States. The company has a P/E ratio of 8.7, below the average drugs industry P/E ratio of 9.1 and below the S&P 500 P/E ratio of 17.7.

Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates WuXi PharmaTech (Cayman as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. You can view the full WuXi PharmaTech (Cayman Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

For more information on WuXi PharmaTech (Cayman) Inc. click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.